[HTML][HTML] TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
Background Osimertinib is a potent, third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI). The multi-arm phase Ib TATTON study …
(EGFR) tyrosine kinase inhibitor (TKI). The multi-arm phase Ib TATTON study …
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
GR Oxnard, JCH Yang, H Yu… - Annals of oncology …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Osimertinib is a potent, third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI). The multi-arm phase Ib TATTON study …
(EGFR) tyrosine kinase inhibitor (TKI). The multi-arm phase Ib TATTON study …
[引用][C] TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
GR Oxnard, JCH Yang, H Yu, SW Kim, H Saka… - Annals of …, 2020 - cir.nii.ac.jp
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or
durvalumab in EGFR-mutant lung cancer | CiNii Research CiNii 国立情報学研究所 学術情報 …
durvalumab in EGFR-mutant lung cancer | CiNii Research CiNii 国立情報学研究所 学術情報 …
TATTON: a multi-arm, phase lb trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
GR Oxnard, JCH Yang, H Yu, SW Kim… - ANNALS OF …, 2020 - scholarworks.bwise.kr
Background: Osimertinib is a potent, third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI). The multi-arm phase lb TATTON study …
(EGFR) tyrosine kinase inhibitor (TKI). The multi-arm phase lb TATTON study …
[HTML][HTML] TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
GR Oxnard, JCH Yang, H Yu, SW Kim… - Annals of …, 2020 - annalsofoncology.org
Background Osimertinib is a potent, third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI). The multi-arm phase Ib TATTON study …
(EGFR) tyrosine kinase inhibitor (TKI). The multi-arm phase Ib TATTON study …
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.
GR Oxnard, JC Yang, H Yu, SW Kim… - Annals of Oncology …, 2020 - europepmc.org
Background Osimertinib is a potent, third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI). The multi-arm phase Ib TATTON study …
(EGFR) tyrosine kinase inhibitor (TKI). The multi-arm phase Ib TATTON study …